All News

The Food and Drug Administration approved the second biomarker-based indication for Keytruda to treat adult and pediatric patients with unresectable or metastatic TMB-H solid tumors across cancer types, including rare cancers.

After a median follow-up of 13.3 months, the median overall response rate across all patients who received idecabtagene vicleucel (ide-cel) was 73%, including a complete response of 33%.

The Food and Drug Administration (FDA) extended the indication of Mylotarg (gemtuzumab ozogamicin) to include the treatment of children aged one month or older with newly diagnosed CD33-positive acute myeloid leukemia (AML).

A cancer survivor deals with virtual examinations and how they can feel impersonal.

"These results suggest that infigratinib has activity in patients with advanced urothelial carcinoma, regardless of the line of treatment,” says lead study author Dr. Yung Lyou.

The Food and Drug Administration (FDA) has approved Zepzelca (lurbinectedin) for adults with metastatic small cell lung cancer (SCLC) whose disease progressed on or after receiving platinum-based chemotherapy.

The phase 3 PROTECTIVE-2 (Study 106) trial met its primary and secondary end points in preventing chemotherapy-induced neutropenia following treatment with plinabulin in combination with Neulasta.

Multitasking isn't an exact science and its ok, often better, to take things one at a time on the cancer journey.

The combination of mirvetuximab soravtansine and Avastin (bevacizumab) demonstrated encouraging overall response rates in patients with ovarian cancer, regardless of the disease’s previous responsiveness to platinum-based chemotherapy, according to data presented at the 2020 ASCO Virtual Scientific Program.

A caregiver sheds light on the trials and tribulations of his wife's cancer journey and describes his awe in watching his wife's strength.

Individuals living with myeloproliferative neoplasm (MPN) often face a markedly different experience compared to those patients with other types of blood cancer. Unfortunately, there tends to be less known about this population due to its smaller size. But tools like the recently published “Blood Cancer in America” 2020 survey aim to help highlight the disparities faced by the MPN community and give a voice to those who may feel unheard.

Sometimes on the cancer journey, the side effects of treatment are not always the ones you expect.

From the American Cancer Society laying off 1,000 employees due to the economic impact of COVID-19 to former Senate Majority Leader Harry Reid announcing his cancer is in remission after receiving an experimental treatment, here’s what’s making the headlines in the cancer space this week.

At a median follow-up of 19.7 months, patients who received the combination achieved an objective response rate (the proportion of patients who had a complete or partial response to treatment) of 27%.

“On the basis of these results, (LuPSMA) appears to represent a new class of effective therapy for men with metastatic castration-resistant prostate cancer,” said Dr. Michael S. Hofman.

The Food and Drug Administration approves Nyvepria, the biosimilar to Neulasta, to help treat and prevent infections in patients undergoing myelosuppressive chemotherapy.

A simple banana split can be a powerful memory, and a powerful tool, to help caregivers and patients find the strength to keep going on their cancer journey.

CURE is kicking off its summer recipe series "Cooking With Cure". Through the summer, we'll be highlighting simple and healthy recipes recommended by oncology dieticians from the John Theurer Cancer Center for patients with cancer and survivors. First up, is a fresh pasta dish with sardines, capers and sundried tomatoes.

The Food and Drug Administration approved Opdivo for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.

The presentation of the complete data from the NRG-GY004 trial comes just months after AstraZeneca and Merck announced in a press release that the combination failed to meet its primary endpoint of progression-free survival.

Living with lymphedema is challenging and summers can be especially difficult, but with a few helpful tips, it can be an enjoyable time.

“These results provide compelling evidence for early darolutamide (Nubeqa) treatment in men with nonmetastatic CRPC,” lead study author Dr. Karim Fizazi, said in a virtual presentation during the meeting.

The allogeneic “off-the-shelf” CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and a manageable safety profile in patients with pretreated large B-cell and follicular lymphomas.

Even those who have undergone mastectomies can enjoy a vintage bralette. And maybe being more comfortable with who I am, a survivor who did not opt for reconstruction, can be a lesson to others.

Join us online for an informative chronic lymphocytic leukemia webinar on Wednesday, June 17, 2020, at 7 - 8 p.m. ET.

After a median follow-up of 15.8 months, patients within the mCRPC cohort who received the combination achieved an objective response rate of 33%.

Oncology dietician Rachel J. Wong, RD, CSO, LD, has a shelf-stable healthy recipe for you to help you make an easy meal when it's hard to get to the grocery store during the pandemic.

To commemorate National Cancer Survivors Day on June 7, CURE® invited its readers to share their encouraging stories of survival.